PTC Therapeutics, Inc. (NASDAQ:PTCT) announced a corporate update and reported its financial results for the fourth quarter and full-year ended December 31, 2013.2013 was a landmark year for PTC with significant accomplishments achieved across the organization. Our private financing early in the year combined with a very successful IPO positioned us to execute on our strategy of leveraging our scientific platform to bring potentially disease-modifying therapies to patients suffering from rare disorders,” stated Stuart W. Peltz, Ph.D., Chief Executive Officer, PTC Therapeutics, Inc. “As we look ahead to 2014, we are excited to complete enrollment in our confirmatory Phase 3 ACT DMD clinical trial in nonsense mutation Duchenne muscular dystrophy, initiate our confirmatory Phase 3 clinical trial in nonsense mutation cystic fibrosis, and advance our SMA program, partnered with Roche and the SMA Foundation, into clinical development. We also plan to pursue additional indications for ataluren beyond nmDMD and nmCF and expect to initiate a proof-of-concept study for a third indication this year.PTC Therapeutics, Inc. (NASDAQ:PTCT) shares after opening at $24.01 moved to $24.88 on last trade day and at the end of the day closed at $22.40. Company price to sales ratio in past twelve months was calculated as 19.42 and price to cash ratio as 4.73. PTC Therapeutics, Inc. (NASDAQ:PTCT) showed a negative weekly performance of -9.90%.
Pollo Tropical opened its first Texas location this weekend to huge crowds and impressive opening-day sales as Texans showed big support for the Miami-based Caribbean grilled chicken restaurant owned and operated by Fiesta Restaurant Group, Inc. (NASDAQ: FRGI). Fiesta Restaurant Group Inc (NASDAQ:FRGI) shares fell -6.05% in last trading session and ended the day on $40.56. FRGI return on equity ratio is recorded as 15.90% and its return on assets is 2.90%. Fiesta Restaurant Group Inc (NASDAQ:FRGI) yearly performance is 59.18%.
Immunomedics, Inc. (Nasdaq:IMMU) announced that four posters will be presented at the 2014 Annual Meeting of the American Association for Cancer Research to be held in San Diego, CA, from April 5 – 9, 2014. Immunomedics, Inc. (NASDAQ:IMMU) shares moved down -6.05% in last trading session and was closed at $3.88, while trading in range of $3.80-$4.20. Immunomedics, Inc. (NASDAQ:IMMU) year to date performance is -15.65%.
Glu Mobile Inc. (NASDAQ:GLUU) disclosed last week that it had launched a new series of games called the Pirates of Everseas which can be downloaded on all the major mobile O.S like, iOS, android and Microsoft Windows Mobile. The game involves multiple payers pitting their strategic planning and alliance building skills to engage the computer backed villains in scoring points while traversing the oceans across the globe. Glu Mobile Inc. (NASDAQ:GLUU) weekly performance is -7.11%. On last trading day company shares ended up $4.18. Glu Mobile Inc. (NASDAQ:GLUU) distance from 50-day simple moving average is -12.27%. Analysts mean target price for the company is $5.80.